COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00257751
Recruitment Status : Completed
First Posted : November 23, 2005
Last Update Posted : July 6, 2011
Information provided by:
Oslo University Hospital

Brief Summary:
Clopidogrel (Plavix), a platelet ADP receptor antagonist, has become the standard of care to prevent thrombosis in interventional cardiology and is increasingly being used in unstable angina and NSTEMI. An increasing number of patients are referred to emergent or urgent CABG, and several studies, as well as our own experience, have shown that preoperative administration of irreversible platelets inhibitors increase the risk of bleeding complications following CABG.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Procedure: Aprotinine Not Applicable

Detailed Description:
Aprotinine (Trasylol) is a potent antifibrinolytic agent known to reduce bleeding after cardiac surgery. The most commeon practice is to give Trasylol in high doses immediately before surgery, during the operation, and during the first postoperative hours. However, it has also been shown that there is a hemostatic effect of the drug when given in a lower dose postoperatively, but this remains unclear.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving
Study Start Date : March 2004
Actual Primary Completion Date : November 2007
Actual Study Completion Date : November 2007

Primary Outcome Measures :
  1. Perioperative bleeding
  2. Blood transfusions
  3. Reoperation

Secondary Outcome Measures :
  1. Difference in costs related to low/high dose

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
All coronary bypass operations in patients receiving Plavix within the last 7 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00257751

Sponsors and Collaborators
Oslo University Hospital
Layout table for investigator information
Principal Investigator: Eivind Øvrum, MD, PhD Oslo University Hospital
Layout table for additonal information
Responsible Party: Eivind Øvrum, MD, PhD, Oslo Heart Center, Rikshospitalet HF Identifier: NCT00257751    
Other Study ID Numbers: APROT04
First Posted: November 23, 2005    Key Record Dates
Last Update Posted: July 6, 2011
Last Verified: March 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases